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1. Summary 
Heparin is frequently used for treatment of cancer-associated thromboembolism. 
Accumulating clinical evidence indicates that cancer patients treated with unfractionated and 
low-molecular weight heparin survives longer that patients treated by other anticoagulants, 
especially patients in the early stage of a disease. Experimental analysis from a number of 
animal models constantly provides evidence about the ability of heparin to attenuate 
metastasis. The non-anticoagulant activity of heparin on metastasis includes the ability to 
inhibit cell-cell-interaction through blocking of P- and L-selectin, to inhibit extracellular 
matrix protease-heparanase, and to inhibit angiogenesis. This chapter summarizes the current 
experimental evidence on the biology of heparin during cancer progression with the focus on 
potential mechanism of heparin antimetastatic activity.  
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2. Heparin affects on cancer: clinical evidence 
The close relationship between cancer and venous thromboembolism (VTE) has been 
recognized for a long time, and multiple risk factors during malignancy have been linked to 
hypercoagulability. Thromboprophylaxis with unfractionated heparin and low-molecular 
weight heparin (LMWH) has been used for management of hypercoagulable state in cancer 
patients, and LMWH is the recommended anticoagulant regimen by international guidelines 
[1, 2]. Many retrospective analyses of clinical data indicated that heparin treatment affects 
survival of cancer patients with various tumors, especially in patients with the early stage of a 
disease [3-5]. Based on these observations several prospective clinical trials has been 
performed to evaluate heparins for its anticancer potential [6-14]. The CLOT study was 
designed to study the effect of LMWH or an oral anticoagulant – Coumarin on prevention of 
venous thromboembolism in patients with solid tumors [6, 7]. While this study showed no 
overall effect on cancer progression, a significant increase in patient survival was detected in 
a subgroup of patients that were without metastasis at the beginning of the trial [6]. 
Furthermore the treatment with LMWH – Nadroparin was significantly more effective than 
the oral anticoagulant [7]. In a trial of patients with small cell lung cancer, the use of LMWH 
– Dalteparin in parallel to standard chemotherapy significantly prolonged median survival of 
patients when compared to patients with the chemotherapy only [9]. However, no significant 
difference was observed in a study of advanced cancer patients treated with Nadroparin for a 
prolonged time [12]. The Fragmin Advanced Malignancy Outcome Study (FAMOUS) trial 
evaluated the effect of Dalteparin in 374 patients with advanced malignancies treated for a 
year [8]. While in patients with originally poor prognosis no statistically significant increase 
in survival was detected, in patients with a better prognosis Dalteparin treatment resulted in a 
significant improvement of patient survival. The Malignancy and LMWH Therapy (MALT) 
trial of patients with advanced cancer of various origins demonstrated an improvement of 
survival when compared to a control group [11]. The subgroup analysis of patients with a 
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better prognosis in the MALT and FAMOUS studies further underlines the potential of 
heparins to affect earlier stages of cancer. There are several ongoing clinical trials with an aim 
to validate the effect of heparin on cancer progression in specific cancer types. Nevertheless, 
the available evidence about heparin activity in cancer patients obtained from several 
completed studies indicates that heparin seems to directly affect cancer progression.  
 
3. Heparin attenuates metastasis in experimental models 
The effect of heparin on cancer progression has been reported by a number of laboratories, 
most of which used a mouse model of experimental metastasis [reviewed in 15-17]. In the 
initial studies, application of unfractionated heparin attenuated metastasis of mammary 
carcinoma and melanoma cells [18, 19]. Despite many limitations of the experimental 
metastasis model, the direct application of tumor cells in the circulation allows a more 
detailed analysis of heparin inhibitory potential that is limited to a timely defined presence of 
heparin in the circulation. The application of heparin around the time of tumor cell injection 
resulted in attenuation of metastasis that was observed in the majority of studies using 
different tumor cell lines, a wide range of heparin doses and a variety of heparin preparations 
[see reviews 15-17]. A single dose of heparin effectively attenuated metastasis of human and 
mouse colon carcinoma and melanoma, mouse breast carcinoma and lung carcinoma. 
Application of heparin either 24 hours before, or after the tumor cell injection had no effect 
[19, 20]. Attenuation of metastasis was generally independent of the route of heparin 
application. While intravenous application of heparin around the time of tumor cell injection 
always led to a reduction of metastasis, subcutaneous or intraperitoneal application of heparin 
were mostly effective [16, 21-24]. The observed limited response to heparin has been likely 
due to variations in time and/or route of heparin application, amounts of applied heparins and 
differences in heparin preparations used [21-24]. In the majority of studies the amount of 
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heparin applied significantly exceeded the clinically used therapeutic dose. Nevertheless, 
recent studies provided evidence that heparin attenuated metastasis in two different mouse 
models also at clinically relevant concentrations [25, 26]. Taken together, a number of animal 
experiments convincingly support the ability of heparins to attenuate metastasis. Mouse 
model of experimental metastasis proved to be instrumental for narrowing down the potential 
mechanism underlying the heparin activity during cancer progression (see below). However, 
this model had several limitations which do not allow to analyze the various stages of 
metastasis or the root of metastasis (lymphatic versus hematogenous). Heparin has been 
shown to attenuate metastasis only in one study with a spontaneously metastatic mouse 
model, while tumor growth remained largely unaffected [27]. Further studies in spontaneously 
metastatic mouse models are required to confirm the findings from experimental models with 
the primary focus on an identification of the potential mechanism of heparin activity in this 
process.  
 
4. Diverse biological activities of heparin 
Heparin is a complex mixture of natural glycosaminoglycans that contains a variety of 
biological activities. Heparin molecules are long unbranched polymers built of disaccharide 
repeats consisting of glucosamine and iduronic/galacturonic acid with a high degree of 
sulfation. Heparin is found in granules of mast cells that line blood vessels and are also 
present in mucosal tissues. Clinical preparations of heparin are of porcine and bovine origins 
that are adjusted according to their anticoagulant activity. The molecular weight of an 
unfractionated heparin ranges between 12,000 – 14,000 Da. The partially depolymerized and 
fractionated LMWH consist of fragments with an average size of 5,000 Da. Although LMWH 
preparations differ from each other depending on the preparation method, chemical or 
enzymatical depolymerization, their pharmacokinetical parameters are comparable [28]. The 
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anticoagulant activity of heparin is defined by its ability to bind antithrombin III. A distinct 
pentasaccharide structure has been identified as the active site of heparin [29]. But this 
pentasaccharide represent only a small fraction of heparin preparations. Heparin binding to 
antithrombin alters its conformation and thereby accelerates its antithrombotic activity. The 
heparin –antithrombin complex binds to an active factor X with a high affinity thereby 
inactivating the factor Xa. While unfractionated heparin and LMWH have comparable anti Xa 
activities, they differ in their ability to inhibit factor IIa [30]. Binding of factor IIa requires a 
formation of a complex around a longer chain of the heparin fragment than is usually not 
present in LMWH preparations.  
Heparin preparations are mixtures of heterogenous polysaccharides containing a large variety 
of biological activities, which makes the identification of the heparin role during cancer 
progression rather complicated. There is accumulating evidence that heparin, apart from its 
anticoagulant activity, can block P- and L-selectin, affect activity of growth factors and 
cytokines, release tissue factor pathway inhibitor (TFPI), inhibit heparanase and angiogenesis, 
alter interactions with integrins and modulate protease activity and thereby the composition of 
extracellular matrix [15, 29, 31-35]. While any of these activities may affect cancer 
progression (Figure 1), the experimental evidence from a number of studies strongly indicates 
that heparin affects early events in the metastatic cascade.  
 
5. Potential mechanisms of heparin affecting cancer progression 
Metastasis is a process during which invasive tumor cells enter the circulation, avoid immune 
responses, attach to the endothelium of distant organs, extravasate from the vasculature and 
establish metastatic foci. The common observation in most animal studies that a single dose of 
heparin before tumor cell injections attenuates metastasis strongly indicates that heparin 
affects the initial phase of hematogenous metastasis. This observation is further supported by 
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the fact that the half-life of heparin in circulation ranges between four to six hours [36, 37]. 
Despite the relatively short time of heparin availability in the circulation, heparin significantly 
modulates the metastatic capacity of tumor cells while they are still in the circulation. Thus, 
heparin is affecting immediate processes upon tumor cell injection into the circulation like 
inhibition of P-and L-selectin-mediated interactions and affecting coagulation. Consequently, 
the inhibitory affect of heparin on angiogenesis or extracellular matrix remodeling are 
unlikely to be affected during this period. 
 
6. Anticoagulant activity of heparin 
Cancer patients are prone to thrombotic complications and LMWH and UFH are used as an 
effective therapeutic anticoagulant treatment or as a prophylaxis [38]. A retrospective analysis 
of a number of clinical trials, where heparin treatment was compared with other anticoagulant 
regimen (e.g. Coumarin), indicated that heparin exerts activity beyond its anticoagulation [29, 
39, 40]. Heparin effect on cancer progression has been confirmed in animal models and has 
been found to be additional to its anticoagulant activity [15, 17, 41]. The use of modified 
heparins with minimal or no anticoagulant activity led to attenuation of metastasis in a 
number of various mouse models using different cancer cell lines, indicating that heparin 
affects metastasis largely in an anticoagulant independent manner [19, 21, 22, 27, 37, 42-44]. 
The use of an anti-thrombin inhibitor, hirudin, have been shown to reduce metastasis but the 
used amount of hirudin was strongly exceeding clinically relevant concentrations [45, 46]. 
The identification of a pentasaccharide reponsible for the antithrombin inhibitory activity in 
the heparin sequence enabled to evaluate the anti-cancer activity of heparin [47]. While the 
synthetic pentasaccharide – fondaparinux did not affect cancer progression, LMWH 
effectively attenuated metastasis at clinically tolerable levels [25, 26] However, the 
antimetastatic activity of LMWH has been found to vary among different preparations.  
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Heparins have also the ability to release tissue factor pathway inhibitor (TFPI) from the blood 
vessel walls and thereby affect metastasis [35]. Application of LMWH – Tinzaparin led to a 
reduction of metastasis. Intravenous injection of recombinant TFPI at the time of tumor cell 
injection significantly attenuated metastasis of melanoma [35, 48]. The extent of heparin 
mediated TFPI release and its contribution to inhibition of cancer progression requires further 
in vivo investigation in the context of other non-anticoagulant activities of heparin.   
 
7. Inhibition of heparanase 
Tumor cells invasion is an essential step of cancer progression that is associated with an 
ehnaced capability of tumor cells to degrade extracellular matrix components, including 
heparin sulfate proteoglycans, collagens and fibronectin [49]. Tumor cells produce several 
hydrolytic enzymes including matrix metalloproteinases and heparanase, and their expression 
correlates with their metastatic potential. Heparanase is an endoglycosidase that cleaves 
heparin sulfate. Elevated heparanase expression has been detected in association with cancer 
progression of several carcinomas including colon, liver, pancreas, bladder, breast and 
prostate carcinoma as well as leukemia and multiple myeloma [50-52]. Heparanase 
overexpression in human tumors confers accelerated tumor growth and invasive phenotype in 
experimental animals [52]. Silencing of the heparanase gene in cancer cells resulted in a 
reduced angiogenesis, tumor growth and metastasis, thereby directly linking heparanase 
activity to cancer progression [53]. Several studies provided evidence that heparin inhibits 
heparanase activity in vitro and that modified heparins without anticoagulant activity but 
heparanase inhibitory activity attenuated metastasis of melanomas and multiple myelomas 
[19, 54, 55]. Furthermore, sulfated oligosaccharides and laminarin sulfate with heparanase 
inhibitory activity attenuated experimental metastasis of melanomas and breast carcinomas 
[56, 57]. Heparanase has been shown to regulate the function of heparan sulfate and thereby 
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affect tumor growth and metastasis in multiple myeloma [54, 58]. Shedding of heparan sulfate 
proteoglycan syndecan-1 from myeloma cells into their microenvironment is mediated by 
heparanase and is critical for the cancer progression [54]. The use of a heparanase-specific 
modified heparin NA-ROH (100%-N-acetylated, 25% glycol-split) attenuated primary tumor 
growth and metastasis [54, 55]. Recently, the effect of NA-ROH heparin has been tested also 
in colon carcinomas, where no attenuation of metastasis was observed [37]. Therefore, 
inhibition of heparanase leads to attenuation of metastasis only in tumor cells expressing this 
enzyme.  
 
8. Selectins as potential targets of heparin 
Unfractionated heparin has been found to be an efficient ligand for P- and L-selectin [59, 60]. 
Selectins are vascular cell adhesion molecules involved in adhesive interactions of platelets, 
leukocytes and endothelial cells within the blood circulation. The physiological role of 
selectins has been described in hemostasis, inflammation and immune response [61, 62]. 
Selectins mediate the initial interactions of leukocytes with the vascular endothelium. The 
rapid and reversible interactions between selectins and their carbohydrate ligands enable 
leukocyte rolling that may result in firm adhesion. There are three members of the selectin 
family: L-, P- and E-selectin. While L-selectin is constitutively expressed on the almost all 
leukocyte populations, P-selectin is constitutively expressed in the secretory granules of 
platelets and endothelial cells. Upon activation, P-selectin is rapidly expressed on the cell 
surface of both endothelial cells and platelets, thereby initiating cell adhesion. E-selectin 
expression on endothelial cell surfaces requires de novo transcription, thus occurs several 
hours after activation [63]. Selectin ligands usually carry sialylated, fucosylated lactosamine 
oligosaccharide structures containing the terminal tetrasaccharide sialyl Lewisx or its isomer 
sialyl Lewisa (sLex/a) [63, 64]. Additional sulfation of the glycan itself or of the protein 
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backbone in close proximity to the oligosaccharide further enhances the specific recognition 
by P-and L-selectin [65]. In addition to this common selectin ligand, P- and L-selectin can 
efficiently bind to heparin and sulfated galactosylceramide – sulfatides [59, 60, 66]. The 
ability of selectins to recognize a variety of different carbohydrate structures indicates that the 
lectin domain of selectins binds to a certain carbohydrate “patch“ [67].  
 
9. Carcinomas, heparin and hematogenous metastasis 
Hematogenous metastasis is the common route of cancer spread for epithelial cancer 
carcinoma. Epithelial cells are lining up the lumen of hollow organs that are covered by 
mucins. Cell-surface-mucins as well as soluble mucins secreted on apical sites of the 
epithelium contribute to protection of the organs from pathogens. Mucins are high molecular 
weight molecules that contain a large portion of O-linked glycan structures [68, 69]. 
Carcinoma cells show altered cell surface glycosylation with an enhanced presence of sLex, 
sLea, Tn and sialyl-Tn oligosaccharide structures on mucins [68, 69]. The positive correlation 
between sLex/a expression and poor prognosis, due to metastasis, has been demonstrated in 
colon, gastric, lung, prostate, renal and breast cancers [70-76]. The correlation between 
selectin ligand expression and poor prognosis for carcinoma patients indicates the potential 
involvement of selectins in cancer progression. Moreover, the presence of carcinomas 
carrying selectin ligands in blood circulation makes it possible to mediate interactions with 
selectins on platelet, leukocytes, and endothelium thereby leading to metastasis [16].  
 
10. P- and L-selectin facilitate metastasis 
Hematogenous metastasis is a process consisting of several events enabling the tumor cell to 
leave the primary tumor, enter the blood circulation, evade immune responses, adhere to the 
vascular cells of distant organs and exit from circulation and form the new metastatic lesion. 
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Of these events, cell-cell interactions leading to tumor cells adhesion to the endothelium of 
distant organs appear to be critical for this process [77, 78]. The rapid expression of P-selectin 
on platelets and endothelium upon activation and the constant presence of L-selectin on 
leukocytes further supported the hypothesis that selectins may facilitate metastatic initiation. 
The recent evidence obtained in P- and/or L-selectin deficient mice confirms the contribution 
of these early response receptors to metastasis  [20, 36, 79-82]. Attenuation of metastasis was 
observed in the absence of P-selectin both with carcinomas and melanoma cells expressing 
selectin ligands [20, 36, 37, 80]. The absence of P-selectin led to a reduction of tumor seeding 
to the lung vasculature that was associated with a reduced platelet-tumor cell emboli 
formation [36]. Similarly, the reduction of selectin ligands on tumor cells caused a decrease in 
platelet-tumor cell emboli formation and attenuation of metastasis [36, 80, 83]. The platelet-
tumor cell emboli formation seems to protect tumor cells from elimination by NK cells and 
this process is largely P-selectin dependent [84]. Bone marrow reconstitution of lethally 
irradiated P-selectin deficient mice has shown that also the endothelial P-selectin expression 
contributes to metastasis [20].   
Attenuation of metastasis was observed also in L-selectin deficient mice, strongly implicating 
leukocytes to be active facilitators of this process [80, 81]. L-selectin-mediated recruitment of 
leukocytes to vascular tumor cells was associated with an enhanced expression of L-selectin 
ligands surrounding tumor emboli [81]. Intravenous injection of a function blocking L-
selectin antibody resulted in attenuation of metastasis [81].Although the mechanism of 
leukocyte contribution to metastasis requires further investigations, the current evidence 
indicates that leukocytes may potentiate tumor cell extravasation [85-88]. The individual 
absence of P- or L-selectin significantly attenuated metastasis of carcinoma cells, but in the P- 
and L-selectin double deficient mice virtually no metastasis was observed [80]. These 
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observations strongly indicate a synergistic effect of both selectins during initiating steps of 
metastasis.  
The over-expression of E-selectin in the liver was shown to divert metastasis to this organ 
[89].  In another study, experimental liver metastasis has been shown to be blocked by E-
selectin blocking antibody [90, 91]. In an experimental metastasis model where mice injected 
with IL-1 where co-injected with tumor cells together with soluble E-selectin reduction of 
metastasis to the lungs has been observed [92]. However, the cytokine-induced E-selectin 
expression may not reflect the natural process of metastasis. Interestingly, in the absence of E-
selectin no attenuation of experimental metastasis to the lungs was observed [82]. Due to the 
delayed cell-surface expression, E-selectin may not be affecting the very early steps of 
naturally occurring metastatic processes. Therefore, the presence of early response receptors 
P- and L-selectin in the blood circulation suggests the implication of endothelium, platelets 
and leukocytes in metastasis that can be inhibited by heparins. 
 
11. Heparin inhibits P and L-selectin-mediated interactions 
Heparin was shown to attenuate metastasis in a number of different animal models when 
applied at the time of tumor cells injection [reviewed in 16, 17]. To address the potential of 
heparin in the process to affect tumor cell invasion and migration into the blood vessels, 
spontaneous metastatic models are necessary. Nevertheless, the widely used experimental 
metastasis model enables to characterize the molecular mechanisms underlying the effect of 
heparin on the initiation phase of metastasis. The antimetastatic activity of heparin was 
analyzed in P- and/or L-selectin deficient mice [20, 36, 37, 80, 81, 93]. Injection of heparin 
shortly before tumor cell injection attenuated metastasis in wild type (wt) mice to similar 
levels as observed in P-selectin deficient mice (Psel-/-) [20, 36, 80]. Heparin injection shortly 
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before tumor cell injection further attenuated metastasis in L-selectin deficient mice (Lsel-/-) 
[80, 81]. This heparin administration efficiently inhibited platelet-tumor cell emboli formation 
that was shown to be largely P-selectin dependent [36]. No additional reduction of metastasis 
was observed by heparin in Psel-/- mice [20, 36, 80]. Attenuation of metastasis was also 
achieved with heparin derivatives without anti-coagulant activity together with the finding 
that heparin showed no effect in Psel-/- mice, heparin treatment at time when tumor cell are in 
circulation likely influence P-selectin mediated interactions during early steps of metastasis 
[37]. 
The additional attenuation of metastasis achieved by heparin treatment at time of tumor cell 
injection in Lsel-/- mice indicates that P-selectin-mediated platelet aggregation precedes the 
involvement of L-selectin, thereby leukocytes in this process [81]. Accordingly, heparin 
treatment several hours post-tumor cell injection – late heparin (6-12 h) further attenuated 
metastasis in Psel-/- mice, while had no further effect in Lsel-/- mice [81]. The late heparin 
treatment in wt mice resulted in attenuation of metastasis to a similar extent as observed in 
Lsel-/- mice. The final evidence that heparin affects primarily P- and L-selectin mediated 
interactions came from the P- and L-selectin double deficient mice [80]. Heparin treatment, 
either shortly before or later, after tumor cell injection had no further effect on metastasis. 
Interestingly, prolonged treatment of P- and L-selectin double deficient mice with high doses 
of UFH further reduced metastasis, indicating heparin affect on other mechanisms of 
metastatic progression [93]. Recently, different clinically used LMWH preparations have 
been shown to attenuate metastasis by inhibition of selectin [25, 26].  
 
12. Mechanism of heparin action during metastasis 
Hematogenous metastasis is directly or indirectly responsible for most cancer-related deaths. 
Accumulating evidence from a number of laboratories indicates that heparin attenuates 
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experimental metastasis of various cancer cells, as long as dose of heparin or its derivative 
reaches the clinically used concentration and is applied around the time when tumor cells are 
still in the circulation [reviewed in 16, 17]. There have been only two exceptions, where 
heparin did not affect metastasis applied around the time of tumor cell injection [22, 
23].Heparin treatment of mice either 1 day before or 1 day after tumor cell injection did not 
affect metastasis [19, 20]. Despite the large variation of heparin doses applied, attenuation of 
metastasis has been observed. Human P-selectin sensitivity is about ten fold higher when 
compared to mouse P-selectin [36]. The affectivity of non-anticoagulant heparins as 
metastatic inhibitors further excludes the possibility that the inhibition of prothrombotic 
activities is the main mechanism of heparin anti-cancer activity [19, 27, 37]. Basically, all 
published studies using heparin or its derivatives in experimental metastasis models are in 
agreement with the potential inhibition of P- and/or L-selectin function. While other 
biological activities can clearly contribute to anti-metastatic activity of heparin, the relatively 
short time of heparin presence in the circulation makes them less likely to be affective in this 
context. Further analyses of heparin as an inhibitor of cancer progression are required and 
should validate heparin as an inhibitor of cancer progression in spontaneously metastatic 
mouse models. Analysis of P-and/or L-selectin inhibitors during metastasis might 
complement the knowledge about this process. Yet, the very nature of heparin, carrying not 
only selectin-inhibitory activity but also the activity towards heparanase, binding of cytokines, 
TFPI release or modulatory activities on extracellular matrix, might prove beneficial over a 
single targeting of selectins. Together with the currently available clinical evidence from 
already performed clinical trials as well as ongoing trials supports the future evaluation of 
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Figure Legend 
Figure 1 Diverse biological activities of heparin potentially affecting cancer progression. 
Heparin may affect any of these activities and thereby inhibit cancer progression. Many of 
these activities have been shown in vitro and the individual contribution to attenuation of 
cancer progression remains to be determined in vivo.  
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